---
title: "CANF.US (CANF.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CANF.US/news.md"
symbol: "CANF.US"
name: "CANF.US"
parent: "https://longbridge.com/en/quote/CANF.US.md"
datetime: "2026-05-22T01:31:06.189Z"
locales:
  - [en](https://longbridge.com/en/quote/CANF.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CANF.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CANF.US/news.md)
---

# CANF.US (CANF.US) — Related News

### [Can-Fite (CANF.US) sees volatility, shares down intraday](https://longbridge.com/en/news/284800271.md)
*2026-04-30T15:20:50.000Z*
> Can-Fite BioPharma（CANF.US）现价 $2.940，当日 -1.67%，盘中 5 分钟涨幅曾超 3%，市值 0.04 亿。企业聚焦创新药物研发，近期临床 2a 期积极数据推动股价剧烈波动。此前合作方 Vetbiolix

### [Can-Fite BioPharma Rallies 24% on Positive Trial Data](https://longbridge.com/en/news/284784837.md)
*2026-04-30T13:43:18.000Z*
> Can-Fite BioPharma（CANF.US）现价 $3.726，当日 +24.62%，盘中涨幅显著，市值 0.04 亿。Can-Fite 专注创新药物研发，胰腺癌临床 2a 期试验数据积极，推动股价强势上行。公司近期还公布肝癌患者

### [Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months | CANF Stock News](https://longbridge.com/en/news/284771384.md)
*2026-04-30T04:31:00.000Z*
> Can-Fite BioPharma Ltd. announced positive Phase 2a clinical data for namodenoson in advanced pancreatic cancer, showing

### [Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 | CANF Stock News](https://longbridge.com/en/news/281008477.md)
*2026-03-30T03:20:35.000Z*
> Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Dat

### [Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient | CANF Stock News](https://longbridge.com/en/news/280640690.md)
*2026-03-26T05:31:13.000Z*
> Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic 

### [Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance | CANF Stock News](https://longbridge.com/en/news/279424951.md)
*2026-03-17T03:50:42.000Z*
> Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance | CANF Stock News